Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Lu-177 PSMA”

107 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 107 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT06004661
What this trial is testing

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 23
Testing effectiveness (Phase 2)Looking for participantsNCT05413850
What this trial is testing

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Who this might be right for
Prostate CancerMetastatic Castration-resistant Prostate CancermCRPC+3 more
Blue Earth Therapeutics Ltd 82
Large-scale testing (Phase 3)Looking for participantsNCT06855277
What this trial is testing

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 940
Early research (Phase 1)Not Yet RecruitingNCT07090369
What this trial is testing

Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Peter MacCallum Cancer Centre, Australia 20
Early research (Phase 1)Study completedNCT06641219
What this trial is testing

Clinical Evaluation of [177Lu]Lu-BQ7876 for Targeting of Prostate-Specific Membrane Antigen

Who this might be right for
Prostate Cancers
Tomsk National Research Medical Center of the Russian Academy of Sciences 7
Post-approval studies (Phase 4)Looking for participantsNCT07169825
What this trial is testing

Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function

Who this might be right for
Lu-177 PSMA
M.D. Anderson Cancer Center 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT04663997
What this trial is testing

177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

Who this might be right for
Prostate Cancer
Canadian Cancer Trials Group 200
Not applicableLooking for participantsNCT06200558
What this trial is testing

ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa

Who this might be right for
Prostate Cancer
Hospital of Macerata 534
Not applicableLooking for participantsNCT06450548
What this trial is testing

Dynamic 68Ga-PSMA and 18F-FDG PET/CT Analysis Prior to 177Lu-PSMA

Who this might be right for
Prostate Cancer Metastatic
Centre Henri Becquerel 60
Not applicableStudy completedNCT06830408
What this trial is testing

Performance of 177Lu-PSMA-I&T for RLT in mCRPC - Prospective Multicenter Swiss Registry Study

Who this might be right for
mCRPC
University Hospital, Basel, Switzerland 250
Testing effectiveness (Phase 2)Study completedNCT03454750
What this trial is testing

Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC)

Who this might be right for
Metastatic Castration Resistant Prostate Cancer68Ga-PSMA PET/CT Positive
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 143
Large-scale testing (Phase 3)Not Yet RecruitingNCT07795268
What this trial is testing

Study to Evaluate the Efficacy and Safety of 177Lu-NYM032 Injection in Participants With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer
Norroy Bioscience Co., LTD 600
Testing effectiveness (Phase 2)Study completedNCT05114746
What this trial is testing

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 94
Large-scale testing (Phase 3)Looking for participantsNCT05939414
What this trial is testing

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Who this might be right for
Oligometastatic Prostate Cancer (OMPC)
Novartis Pharmaceuticals 450
Not applicableWithdrawnNCT03596710
What this trial is testing

Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resistant Prostate Cancer Undergoing Radioligand Therapy

Who this might be right for
Castration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IV Prostate Cancer
Jonsson Comprehensive Cancer Center
Not applicableUnknownNCT06433063
What this trial is testing

Effect of Hypoxia on FMISO PET to Response to Lu-177 PSMA Treatment

Who this might be right for
Prostatic NeoplasmsHypoxia
Cigdem Soydal 30
Early research (Phase 1)Looking for participantsNCT07223034
What this trial is testing

177Lu-PSMA-617 in People With Gliomas

Who this might be right for
GliomaDiffuse Astrocytoma, IDH-Wildtype (Grade 2-4)Glioblastoma, IDH-wildtype+3 more
Memorial Sloan Kettering Cancer Center 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT05849298
What this trial is testing

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

Who this might be right for
Prostatic Neoplasm
Novartis Pharmaceuticals 49
Testing effectiveness (Phase 2)Looking for participantsNCT06084338
What this trial is testing

Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc

Who this might be right for
Prostate Cancer
VA Office of Research and Development 60
Not applicableLooking for participantsNCT06720532
What this trial is testing

Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177Lutetium-PSMA Radioligand Therapy: a Prospective Observational Study - KiRi-Trial

Who this might be right for
Kidney DiseaseRadiation NephropathyMetastatic Castrate Resistant Prostate Cancer (mCRPC)
Hannah Schaefer 100
Next Page